Marelius® Biopharma Group Ltd
Biopharma | Regulatory | Clinical Services
About Us
Marelius® Biopharma Group Ltd is a specialist biopharmaceutical and life-sciences organisation providing regulatory, clinical, and strategic support to biotechnology and therapeutics programmes operating in highly regulated environments.
Strategic Support
Comprehensive guidance across regulatory strategy, clinical development, and international execution, helping programmes progress efficiently from early development.
Global Execution
Evidence-based strategies and cross-border operational capabilities that support market-facing stages across multiple international jurisdictions.
Scientific Depth
Collaborating closely with sponsors, investigators, and regulatory authorities to combine scientific rigor with commercial insight.
Marelius® Biopharma Group Ltd operates within the Marelius group, which includes Marelius Inc. (OTCID: MBPG), a publicly traded life-sciences company.
Regulatory Expertise
Deep experience across major regulatory frameworks
FDA
U.S. Food & Drug Administration
IND · NDA · BLA Filings
EMA
European Medicines Agency
IMPD · MAA Procedures
MHRA
UK Medicines Regulator
UKCA · Post-Brexit Strategy
DEA
Drug Enforcement Administration
Controlled Substances
Core Capabilities
Manufacturing Services
Specialised contract manufacturing support for the biopharmaceutical industry.
- Small-Scale Contract Manufacturing
- GMP Compliance (FDA, EMA, MHRA)
- Advanced Technology & Equipment
Related: Regulatory · Training
Professional Training
Elevating standards through comprehensive education and hands-on GMP workshops.
- Online Regulatory Courses
- In-Person GMP Facilities
- Tailored Corporate Training Solutions
Related: Regulatory · Training
Advanced Regulatory Pathways
Navigating regulatory ambiguity in ‘High-Trust’ nodes.
- Senior-led strategy for Early Clinical Design
- IND/IMPD filings management
- Cross-border licensing (DEA/MHRA) for complex frontiers
Related: Regulatory · Training
Venture Advisory & Equity
Moving beyond the fee-for-service model to align with long-term outcomes.
- Advisory contracts linked to equity
- Capital deployment for Cell & Gene / CNS
- Shared-risk commercial models
Related: Regulatory · Training
Operational Focus
arelius® Biopharma Group Ltd continues to support biotechnology and therapeutics programmes through regulatory strategy, clinical development support, and international execution. The company operates as part of the Marelius group, which includes Marelius Inc. (OTC: IDMBPG), and works with sponsors, investigators, and strategic partners across regulated healthcare environments.
Leadership
Dr Abel N. J. Haque
B.Med Sci (Hons), BM BS
Dr Haque leads Marelius® Biopharma Group Ltd with over 35 years of international experience in healthcare, biotechnology, and life sciences. His career includes senior executive roles at Stryker Corporation (NYSE: SYK) and Wright Medical Group (NASDAQ: WMGI), and he currently serves as CEO of Marelius Inc. (OTCID: MBPG).
Dr Haque’s leadership combines clinical insight with deep regulatory and commercial expertise, managing teams and consultants to support clients through complex development pathways across FDA, EMA, and MHRA jurisdictions.
Registered Office
Marelius Biopharma Group Ltd
Shell-Mex House, 80 Strand
London WC2R 0DT
United Kingdom
© 2026 Marelius Biopharma Group Ltd. All Rights Reserved.
Company Details
Registered in England & Wales
Company No: 15950715
ICO Ref: ZC089462
Privacy Policy
Group Structure
Marelius® Biopharma Group Ltd is a private limited company operating within the Marelius group.
References to Marelius Inc. (OTCID: MBPG) relate to the group structure.